(ALLO) – PRNewswire
-
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.
-
Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies
-
Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics
-
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR Tâ„¢) Therapies
Back to ALLO Stock Lookup